Pill imprint Pfizer CRZ 250 has been identified as Xalkori 250 mg.
Xalkori is used in the treatment of non-small cell lung cancer and belongs to the drug class multikinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Xalkori 250 mg is not subject to the Controlled Substances Act